# Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

> **NCT03308201** · PHASE1 · COMPLETED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 55 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Hemay022+exemestane
- **DRUG:** Hemay022+letrozole
- **DRUG:** Hemay022+ fulvestrant

## Key facts

- **NCT ID:** NCT03308201
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-03-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308201, "Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03308201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*